Next |
home / stock / kalv / kalv message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $KALV hod6.24 | znewcar1 | investorshangout | 12/28/2022 7:21:21 PM |
I would not even buy the shares at $20. | Femto99 | investorshub | 02/11/2021 5:16:09 PM |
All in puts! | Femto99 | investorshub | 02/11/2021 4:02:31 PM |
znewcar1: KALV 114% v34,8M c33.50 f17,9M preMH51.3 HOD44.7 S28.9 | znewcar1 | investorshangout | 02/09/2021 9:17:38 PM |
Boom! Killed it with puts today! | Stock_Barber | investorshub | 02/09/2021 9:01:35 PM |
* * $KALV Video Chart 02-09-2021 * * | ClayTrader | investorshub | 02/09/2021 8:58:07 PM |
This company is a disaster... | Stock_Barber | investorshub | 02/09/2021 2:24:13 PM |
The company is delinquent. | make it happen | investorshub | 02/09/2021 2:19:12 PM |
? lol | make it happen | investorshub | 02/09/2021 2:18:59 PM |
They are hemorrhaging money. Have pretty much zero | make it happen | investorshub | 02/09/2021 1:04:05 PM |
$KALV Kalvista Pharma Trend Break | TFMG | investorshub | 06/24/2020 2:23:05 AM |
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland | whytestocks | investorshub | 04/22/2019 6:50:38 PM |
News: $KALV KalVista Pharmaceuticals to Present at Needham | whytestocks | investorshub | 04/03/2019 5:24:23 PM |
$KALV buy 28.87 | stocktrademan | investorshub | 04/02/2019 4:58:09 PM |
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results | whytestocks | investorshub | 03/14/2019 12:20:40 PM |
Where is everyone? | countryrapper2000 | investorshub | 01/07/2018 9:44:49 AM |
$17.85 !! | TheFinalCD | investorshub | 10/10/2017 12:52:38 PM |
Sniffer rocket ship today!! Wheeee. $KALV | Lone Wolf | investorshub | 10/10/2017 12:52:02 PM |
$15.50 now ~ keep rollin | TheFinalCD | investorshub | 10/10/2017 12:48:13 PM |
http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmace | kondziu | investorshub | 02/10/2017 10:38:41 AM |
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable...